Presented below is a summary of the compensation cost recognized in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025.


	Three Months Ended March 31,
(in thousands)	2026		2025
Research and development	$	55	$	699
Sales and marketing		-		-
General and administrative		339		1,390
Total	$	394	$	2,089

The table above includes approximately $0.1 million of compensation expense related to the Series D-2 and D-3 Preferred Stock issued in connection with the Ergatta Acquisition (see Note 23), and is reflected in General and administrative expense. For the three months ended March 31, 2026 and 2025, the Company recognized stock-based compensation expense of $0.4 million and $2.4 million, respectively, of which $0.0 million and $0.3 million, respectively, was capitalized as software costs.

During the three months ended March 31, 2026, the Company did not grant any shares under the 2023 and 2020 Plan. The Company has not granted any restricted stock or stock appreciation rights.


	Number of options		Weighted average exercise price		Weighted average remaining contractual term (in years)		Aggregate intrinsic value (in thousands)
Outstanding as of December 31, 2025		7	$	100,644		7.3	$	—
Granted		—	$	—
Exercised		—	$	—
Cancelled or forfeited		—	$	—
Outstanding as of March 31, 2026		7	$	100,644		7.3	$	—
Options exercisable as of March 31, 2026		4	$	513,794		7.2	$	—
Options unvested as of March 31, 2026		3	$	1,738,503		7.4	$	—

As of March 31, 2026 and December 31, 2025, the Company had $0.7 million and $0.9 million of unrecognized stock-based compensation expense that is expected to be recognized over a weighted-average period of 0.2 years and 0.2 years, respectively.